Oral anticoagulant switching in patients with atrial fibrillation: a scoping review
Introduction Oral anticoagulants (OACs) prevent stroke in patients with atrial fibrillation (AF).
Several factors may cause OAC switching. Objectives To examine the phenomenon of OAC …
Several factors may cause OAC switching. Objectives To examine the phenomenon of OAC …
[HTML][HTML] Vitamin-K-antagonist phenprocoumon versus low-dose direct oral anticoagulants (DOACs) in patients with atrial fibrillation: a real-world analysis of German …
L Warkentin, S Hueber, B Deiters, F Klohn… - Thrombosis Journal, 2022 - Springer
Background For stroke prevention in patients with atrial fibrillation (AF), direct oral
anticoagulants (DOACs) have been increasingly prescribed instead of vitamin-K-antagonists …
anticoagulants (DOACs) have been increasingly prescribed instead of vitamin-K-antagonists …
Oral anticoagulant adherence and switching in patients with atrial fibrillation: a prospective observational study
Background Adherence to oral anticoagulants (OACs) in patients with atrial fibrillation (AF) is
important in preventing stroke. The dominance of retrospective studies using administrative …
important in preventing stroke. The dominance of retrospective studies using administrative …
[HTML][HTML] Trends in the prescription of non-vitamin K antagonist oral anticoagulants for atrial fibrillation: Results of the Polish Atrial Fibrillation (POL-AF) Registry
I Gorczyca, O Jelonek, B Uziębło-Życzkowska… - Journal of Clinical …, 2020 - mdpi.com
Background: Current guidelines do not suggest in which groups of patients with atrial
fibrillation (AF) individual non-vitamin K antagonist oral anticoagulants (NOACs) should be …
fibrillation (AF) individual non-vitamin K antagonist oral anticoagulants (NOACs) should be …
[HTML][HTML] Prescribing patterns and outcomes of edoxaban in atrial fibrillation: one-year data from the global ETNA-AF program
TF Chao, M Unverdorben, P Kirchhof… - Journal of Clinical …, 2023 - mdpi.com
Non-recommended dosing occurs in~ 25–50% of non-vitamin K antagonist oral
anticoagulant prescriptions, with limited data for edoxaban. We analyzed edoxaban dosing …
anticoagulant prescriptions, with limited data for edoxaban. We analyzed edoxaban dosing …
[HTML][HTML] Comparative non-persistence in the first year of treatment with oral anticoagulants in patients with atrial fibrillation: A French comprehensive nationwide study
N Danchin, G Steg, I Mahé, O Hanon, F Jacoud… - Archives of …, 2022 - Elsevier
Abstract Background Direct oral anticoagulants (DOACs) were developed as an alternative
to vitamin K antagonists (VKAs) and are commonly used for stroke prevention in patients …
to vitamin K antagonists (VKAs) and are commonly used for stroke prevention in patients …
Die Anwendung von Apixaban bei Patienten mit Vorhofflimmern in der kardiologischen Praxis-eine retrospektive Analyse von 493 Patienten
K Storz - 2023 - archiv.ub.uni-heidelberg.de
Ziel der Arbeit war es, die Apixabandosis zur Antikoagulation bei Patienten mit
Vorhofflimmern anhand der Dosierungsempfehlungen der Fachinformation im klinischen …
Vorhofflimmern anhand der Dosierungsempfehlungen der Fachinformation im klinischen …